GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Debt-to-EBITDA

Chiome Bioscience (TSE:4583) Debt-to-EBITDA : -0.26 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Chiome Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円313.6 Mil. Chiome Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円0.0 Mil. Chiome Bioscience's annualized EBITDA for the quarter that ended in Mar. 2024 was 円-1,208.8 Mil. Chiome Bioscience's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.26.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Chiome Bioscience's Debt-to-EBITDA or its related term are showing as below:

TSE:4583' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.24   Med: -0.11   Max: -0.01
Current: -0.24

During the past 13 years, the highest Debt-to-EBITDA Ratio of Chiome Bioscience was -0.01. The lowest was -0.24. And the median was -0.11.

TSE:4583's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs TSE:4583: -0.24

Chiome Bioscience Debt-to-EBITDA Historical Data

The historical data trend for Chiome Bioscience's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience Debt-to-EBITDA Chart

Chiome Bioscience Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.14 -0.13 -0.15 -0.24

Chiome Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -0.17 -0.31 -0.24 -0.26

Competitive Comparison of Chiome Bioscience's Debt-to-EBITDA

For the Biotechnology subindustry, Chiome Bioscience's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chiome Bioscience's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's Debt-to-EBITDA falls into.



Chiome Bioscience Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Chiome Bioscience's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(291 + 0) / -1211.736
=-0.24

Chiome Bioscience's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(313.6 + 0) / -1208.812
=-0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Chiome Bioscience  (TSE:4583) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Chiome Bioscience Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Chiome Bioscience (TSE:4583) Business Description

Traded in Other Exchanges
N/A
Address
Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience (TSE:4583) Headlines

No Headlines